Constitution of a Prospective Cohort of Patients With Acute Suppurative Hidrosadenitis Followed in the Great West: the COVER Cohort (Verneuil Cohort) (COVER)

August 28, 2025 updated by: Nantes University Hospital
Our primary objective with this cohort will be to define the different phenotypes of acute hidrosadenitis, the characterization of which is essential to define suitable therapeutic approaches. Indeed, our recent data allow us to note that there would be different phenotypes of acute hidrosadenitis and therefore different pathologies inducing different follow-ups and care.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

465

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Angers, France, 49933
      • Brest, France
        • Recruiting
        • CHRU Brest
        • Principal Investigator:
          • Laurent Misery
      • La Roche-sur-Yon, France
      • La Rochelle, France
        • Recruiting
        • CH La Rochelle
        • Contact:
          • Philippe Celerier, MD
      • Le Mans, France
        • Recruiting
        • CH
        • Principal Investigator:
          • Hervé Maillard
      • Lorient, France
        • Recruiting
        • CH Bretagne Sud
        • Contact:
          • caroline JACOBZONE-LEVEQUE
      • Nantes, France
        • Recruiting
        • CHU de Nantes - Dermatologie
        • Contact:
          • Brigitte Dreno, PU PH
        • Principal Investigator:
          • Brigitte Dreno, PU PH
      • Orléans, France
        • Recruiting
        • CHR d'Orléans
        • Contact:
          • eric esteve
      • Poitiers, France
        • Recruiting
        • CHU Milétrie
        • Principal Investigator:
          • Ewa WIERZBICKA-HAINAUT
      • Quimper, France
        • Recruiting
        • CH de Cornouaille
        • Contact:
          • Patrice Plantin
      • Rennes, France
        • Recruiting
        • Chu Pontchaillou
        • Principal Investigator:
          • Alain Dupuy
      • Saint-Brieuc, France
        • Recruiting
        • Ch Saint-Brieuc
        • Contact:
          • gilles safa
      • Tours, France
        • Recruiting
        • CHRU Tours
        • Contact:
          • Annabel Maruani, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

The population studied will relate to patients consulting or being hospitalized for Acute Hidrosadenitis, whatever its severity.

Description

Inclusion Criteria:

  • Patient diagnosed with acute hidrosadenitis by a dermatologist
  • Patient agreeing to be part of the study

Exclusion Criteria:

  • Major under guardianship
  • Protected persons

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patient
Other: no interventional study
no interventional study

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Description of the natural history and identification of the different clinical forms of acute hidrosadenitis
Time Frame: through study completion, an average of 3 years
history of the disease, classification of Hurley, Canoui-Poitrine and van der Zee and Jemec
through study completion, an average of 3 years
Prevalence of severe forms (grade II, III)
Time Frame: through study completion, an average of 3 years
Number of patients with severe disease (grades II and III)
through study completion, an average of 3 years
Definition of different phenotypes of acute hidrosadenitis
Time Frame: through study completion, an average of 3 years
patient history, Canoui-Poitrine and van der Zee and Jemec classification, blood and urine tests, imaging
through study completion, an average of 3 years
Identify the environmental factors associated with the chronicity of the disease
Time Frame: through study completion, an average of 3 years
socio-demographic data
through study completion, an average of 3 years
Identify the environmental factors associated with the chronicity of the disease
Time Frame: through study completion, an average of 3 years
questionnaire for collecting dietary habits
through study completion, an average of 3 years
Identify the environmental factors associated with the chronicity of the disease
Time Frame: through study completion, an average of 3 years
biological nutritional assessment research for a dysmetabolic syndrome
through study completion, an average of 3 years
Identify the environmental factors associated with the chronicity of the disease
Time Frame: through study completion, an average of 3 years
research for a dysmetabolic syndrome
through study completion, an average of 3 years
Identify the environmental factors associated with the chronicity of the disease
Time Frame: through study completion, an average of 3 years
lifestyle questionnaire assessing the impact on quality of life
through study completion, an average of 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Nantes University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 4, 2022

Primary Completion (Estimated)

February 20, 2030

Study Completion (Estimated)

February 20, 2030

Study Registration Dates

First Submitted

April 10, 2020

First Submitted That Met QC Criteria

April 15, 2020

First Posted (Actual)

April 17, 2020

Study Record Updates

Last Update Posted (Estimated)

September 5, 2025

Last Update Submitted That Met QC Criteria

August 28, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RC19_0418

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Hidrosadenitis

Clinical Trials on no interventional study

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe